The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation

American Journal of Transplantation

Volumn 17, Issue 11, 2017, Pages 2790-2802

  Levitsky, J ^a   Formica, R N ^b   Bloom, R D ^c   Charlton, M ^d   Curry, M ^e   Friedewald, J ^a   Friedman, J ^f   Goldberg, D ^c   Hall, S ^g   Ison, M ^a   Kaiser, T ^h   Klassen, D ⁱ   Klintmalm, G ^g   Kobashigawa, J ^j   Liapakis, A ^b   O'Conner, K ^k   Reese, P ^c   Stewart, D ⁱ   Terrault, N ^l   Theodoropoulos, N ^m   Trotter, J ^g   Verna, E ⁿ   Volk, M ^o   more..

^a NORTHWESTERN UNIVERSITY   (United States)

^b YALE UNIVERSITY   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d INTERMOUNTAIN MEDICAL CENTER   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f OPTUM   (United States)

^g BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^h UNIVERSITY OF CINCINNATI   (United States)

ⁱ UNITED NETWORK FOR ORGAN SHARING   (United States)

^j CEDARS SINAI MEDICAL CENTER   (United States)

^k LifeCenter Norwest   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m UNIVERSITY OF MASSACHUSETTS   (United States)

ⁿ Columbia University ^*  (United States)

^o LOMA LINDA UNIVERSITY   (United States)

more..

Author keywords

clinical decision making; clinical research practice; clinical trial design; donors and donation: donor derived infections; education; infection and infectious agents; organ allocation; organ procurement and allocation; organ transplantation in general; viral: hepatitis C

Indexed keywords

ANTIVIRUS AGENT;

ANTIVIRAL THERAPY; BIOETHICS; CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; CONSENSUS DEVELOPMENT; DONOR SELECTION; GRAFT RECIPIENT; HEALTH CARE COST; HEPATITIS C; HUMAN; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MEDICAL SOCIETY; NONHUMAN; ORGAN DONOR; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; THORAX SURGERY; TREATMENT OUTCOME; VIREMIA; VIRUS TRANSMISSION; DONOR; HEPACIVIRUS; PHYSIOLOGY; TRANSMISSION; VIROLOGY;

HEPACIVIRUS; HEPATITIS C; HUMANS; ORGAN TRANSPLANTATION; SOCIETIES, MEDICAL; TISSUE DONORS; VIREMIA;

EID: 85021665485     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.14381     Document Type: Conference Paper

References (98)

1. Belli LS, Berenguer M, Cortesi PA, et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study. J Hepatol 2016; 65: 524–531.
2. Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015; 149: 649–659.
3. Maheshwari A, Thuluvath PJ. Management of acute hepatitis C. Clin Liver Dis 2010; 14: 169–176; x.
4. Kamili S, Drobeniuc J, Araujo AC, Hayden TM. Laboratory diagnostics for hepatitis C virus infection. Clin Infect Dis 2012; 55(Suppl 1): S43–S48.
5. Albertoni G, Castelo Girão MJ, Schor N. Mini review: Current molecular methods for the detection and quantification of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus type 1. Int J Infect Dis 2014; 25: 145–149.
6. Mullis CE, Laeyendecker O, Reynolds SJ, et al. High frequency of false-positive hepatitis C virus enzyme-linked immunosorbent assay in Rakai, Uganda. Clin Infect Dis 2013; 57: 1747–1750.
7. Heinrichs A, Antoine M, Steensels D, Montesinos I, Delforge ML. HCV false positive immunoassays in patients with LVAD: A potential trap! J Clin Virol 2016; 78: 44–46.
8. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36(5 Suppl 1): S35–S46.
9. Humar A, Morris M, Blumberg E, et al. Nucleic acid testing (NAT) of organ donors: Is the ‘best’ test the right test? A consensus conference report. Am J Transplant 2010; 10: 889–899.
10. Stramer SL, Wend U, Candotti D, et al. Nucleic acid testing to detect HBV infection in blood donors. N Engl J Med 2011; 364: 236–247.
11. Abbott KC, Bucci JR, Matsumoto CS, et al. Hepatitis C and renal transplantation in the era of modern immunosuppression. J Am Soc Nephrol 2003; 14: 2908–2918.
12. Gasink LB, Blumberg EA, Localio AR, Desai SS, Israni AK, Lautenbach E. Hepatitis C virus seropositivity in organ donors and survival in heart transplant recipients. JAMA 2006; 296: 1843–1850.
13. Singh N, Neidlinger N, Djamali A, et al. The impact of hepatitis C virus donor and recipient status on long-term kidney transplant outcomes: University of Wisconsin experience. Clin Transplant 2012; 26: 684–693.
14. Vargas HE, Laskus T, Wang LF, et al. Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts. Gastroenterology 1999; 117: 149–153.
15. Testa G, Goldstein RM, Netto G, et al. Long-term outcome of patients transplanted with livers from hepatitis C-positive donors. Transplantation 1998; 65: 925–929.
16. Marroquin CE, Marino G, Kuo PC, et al. Transplantation of hepatitis C-positive livers in hepatitis C-positive patients is equivalent to transplanting hepatitis C-negative livers. Liver Transpl 2001; 7: 762–768.
17. Saab S, Ghobrial RM, Ibrahim AB, et al. Hepatitis C positive grafts may be used in orthotopic liver transplantation: A matched analysis. Am J Transplant 2003; 3: 1167–1172.
18. Ballarin R, Cucchetti A, Spaggiari M, et al. Long-term follow-up and outcome of liver transplantation from anti-hepatitis C virus-positive donors: A European multicentric case-control study. Transplantation 2011; 91: 1265–1272.
19. Lai JC, O'Leary JG, Trotter JF, et al. Risk of advanced fibrosis with grafts from hepatitis C antibody-positive donors: A multicenter cohort study. Liver Transpl 2012; 18: 532–538.
20. Bowring MG, Kucirka LM, Massie AB, et al. Changes in utilization and discard of hepatitis C-infected donor livers in the recent era. Am J Transplant 2017; 17: 519–527.
21. O'Leary JG, Neri MA, Trotter JF, Davis GL, Klintmalm GB. Utilization of hepatitis C antibody-positive livers: Genotype dominance is virally determined. Transpl Int 2012; 25: 825–829.
22. Denniston MM, Jiles RB, Drobeniuc J, et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med 2014; 160: 293–300.
23. KDIGO clinical practice guidelines for the prevention. diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl 2008; S1–S99.
24. Bloom RD, Sayer G, Fa K, Constantinescu S, Abt P, Reddy KR. Outcome of hepatitis C virus-infected kidney transplant candidates who remain on the waiting list. Am J Transplant 2005; 5: 139–144.
25. Cacoub P, Desbois AC, Isnard-Bagnis C, Rocatello D, Ferri C. Hepatitis C virus infection and chronic kidney disease: Time for reappraisal. J Hepatol 2016; 65(1 Suppl): S82–S94.
26. Fabrizi F, Dixit V, Messa P. Impact of hepatitis C on survival in dialysis patients: A link with cardiovascular mortality? J Viral Hepat 2012; 19: 601–607.
27. Fabrizi F, Martin P, Dixit V, Messa P. Meta-analysis of observational studies: Hepatitis C and survival after renal transplant. J Viral Hepat 2014; 21: 314–324.
28. Morales JM, Campistol JM, Dominguez-Gil B, et al. Long-term experience with kidney transplantation from hepatitis C-positive donors into hepatitis C-positive recipients. Am J Transplant 2010; 10: 2453–2462.
29. Kucirka LM, Peters TG, Segev DL. Impact of donor hepatitis C virus infection status on death and need for liver transplant in hepatitis C virus-positive kidney transplant recipients. Am J Kidney Dis 2012; 60: 112–120.
30. Stepanova M, Locklear T, Rafiq N, Mishra A, Venkatesan C, Younossi ZM. Long-term outcomes of heart transplant recipients with hepatitis C positivity: The data from the U.S. Transplant Registry. Clin Transplant 2016; 30: 1570–1577.
31. Koenig A, Stepanova M, Saab S, Ahmed A, Wong R, Younossi ZM. Long-term outcomes of lung transplant recipients with hepatitis C infection: A retrospective study of the U.S. Transplant Registry. Aliment Pharmacol Ther 2016; 44: 271–278.
32. Kumar S, Deo SV, Altarabsheh SE, et al. Effect of hepatitis C positivity on survival in adult patients undergoing heart transplantation (from the United Network for Organ Sharing database). Am J Cardiol 2016; 118: 132–137.
33. Englum BR, Ganapathi AM, Speicher PJ, et al. Impact of donor and recipient hepatitis C status in lung transplantation. J Heart Lung Transplant 2016; 35: 228–235.
34. Fong TL, Cho YW, Hou L, Hutchinson IV, Barbers RG, Herrington CS. Outcomes after lung transplantation and practices of lung transplant programs in the United States regarding hepatitis C seropositive recipients. Transplantation 2011; 91: 1293–1296.
35. Marelli D, Bresson J, Laks H, et al. Hepatitis C-positive donors in heart transplantation. Am J Transplant 2002; 2: 443–447.
36. Ong JP, Barnes DS, Younossi ZM, et al. Outcome of de novo hepatitis C virus infection in heart transplant recipients. Hepatology 1999; 30: 1293–1298.
37. Smith BD, Morgan RL, Beckett GA, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 2012;61(RR-4):1–32.
38. Suryaprasad AG, White JZ, Xu F, et al. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012. Clin Infect Dis 2014; 59: 1411–1419.
39. Yehia BR, Schranz AJ, Umscheid CA, Lo Re 3rd V. The treatment cascade for chronic hepatitis C virus infection in the United States: A systematic review and meta-analysis. PLoS ONE 2014; 9: e101554.
40. Chhatwal J, Wang X, Ayer T, et al. Hepatitis C disease burden in the United States in the era of oral direct-acting antivirals. Hepatology 2016; 64: 1442–1450.
41. Klevens RM, Canary L, Huang X, et al. The burden of hepatitis C infection-related liver fibrosis in the United States. Clin Infect Dis 2016; 63: 1049–1055.
42. Rudd RA, Aleshire N, Zibbell JE, Gladden RM. Increases in drug and opioid overdose deaths: United States, 2000–2014. MMWR Morb Mortal Wkly Rep 2016; 64: 1378–1382.
43. Hagan H, Pouget ER, Des Jarlais DC, Lelutiu-Weinberger C. Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: The influence of time and place. Am J Epidemiol 2008; 168: 1099–1109.
44. Havens JR, Lofwall MR, Frost SD, Oser CB, Leukefeld CG, Crosby RA. Individual and network factors associated with prevalent hepatitis C infection among rural Appalachian injection drug users. Am J Public Health 2013; 103: e44–e52.
45. Klassen DK, Edwards LB, Stewart DE, Glazier AK, Orlowski JP, Berg CL. The OPTN deceased donor potential study: Implications for policy and practice. Am J Transplant 2016; 16: 1707–1714.
46. Theodoropoulos N, Jaramillo A, Ladner DP, Ison MG. Deceased organ donor screening for HIV, hepatitis B, and hepatitis C viruses: A survey of organ procurement organization practices. Am J Transplant 2013; 13: 2186–2190.
47. Kucirka LM, Alexander C, Namuyinga R, Hanrahan C, Montgomery RA, Segev DL. Viral nucleic acid testing (NAT) and OPO-level disposition of high-risk donor organs. Am J Transplant 2009; 9: 620–628.
48. OPTN Policy 2.0 Deceased Donor Organ Procurement (Policy 2). Effective Date 6/1/2017. Available from: http://optntransplanthrsagov/media/1200/optn_policies.pdf.
49. OPTN. Organ Procurement and Transplantation Network Policies. [cited 2017 Jan 1]. Available from: https://optn.transplant.hrsa.gov/media/1200/optn_policies.pdf
50. Theodoropoulos N, Ison M, Jaramillo A. Screening deceased organ donors for infectious diseases: Optimization of testing. ASHI Quarterly 2012; 36: 18–26.
51. Kucirka LM, Sarathy H, Govindan P, et al. Risk of window period hepatitis-C infection in high infectious risk donors: Systematic review and meta-analysis. Am J Transplant 2011; 11: 1188–1200.
52. Annambhotla PD, Gurbaxani BM, Kuehnert MJ, Basavaraju SV. A model to estimate the probability of human immunodeficiency virus and hepatitis C infection despite negative nucleic acid testing among increased-risk organ donors. Transpl Infect Dis 2017; 19: 1–9.
53. Ison MG, Llata E, Conover CS, et al. Transmission of human immunodeficiency virus and hepatitis C virus from an organ donor to four transplant recipients. Am J Transplant 2011; 11: 1218–1225.
54. Levitsky J, Doucette K. Viral hepatitis in solid organ transplantation. Am J Transplant 2013; 13(Suppl 4): 147–168.
55. Elmasry S, Wadhwa S, Bang BR, et al. Detection of occult hepatitis C virus infection in patients who achieved a sustained virologic response to direct-acting antiviral agents for recurrent infection after liver transplantation. Gastroenterology 2017; 152: e558.
56. Koutsoudakis G, Perez-Del-Pulgar S, Forns X. Occult hepatitis C virus infection: Are we digging too deep? Gastroenterology 2017; 152: 472–474.
57. Tokumoto T, Tanabe K, Simizu T, et al. Kidney transplantation from a donor who is HCV antibody positive and HCV-RNA negative. Transplant Proc 2000; 32: 1597–1599.
58. Takeichi T, Asonuma K, Yamamoto H, et al. Liver transplant from an ABO-incompatible and hepatitis C antibody-positive but an HCV-RNA negative living donor in a familial amyloid polyneuropathy patient. Exp Clin Transplant 2013; 11: 182–185.
59. Cruzado JM, Gil-Vernet S, Castellote J, Bestard O, Melilli E, Grinyo JM. Successful treatment of chronic HCV infection should not preclude kidney donation to an HCV negative recipient. Am J Transplant 2013; 13: 2773–2774.
60. Seem DL, Lee I, Umscheid CA, Kuehnert MJ, United States Public Health Service. PHS guideline for reducing human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission through organ transplantation. Public Health Rep 2013; 128: 247–343.
61. AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. Available from: http://www.hcvguidelines.org
62. Terrault N, Berenguer M, Strasser S, et al. International liver transplant society consensus statement on hepatitis C management in liver transplant recipients. Transplantation 2017; 101: 956–967.
63. Nainan OV, Alter MJ, Kruszon-Moran D, et al. Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States. Gastroenterology 2006; 131: 478–484.
64. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556–562.
65. Fan X, Lang DM, Xu Y, et al. Liver transplantation with hepatitis C virus-infected graft: Interaction between donor and recipient viral strains. Hepatology 2003; 38: 25–33.
66. Laskus T, Wang LF, Rakela J, et al. Dynamic behavior of hepatitis C virus in chronically infected patients receiving liver graft from infected donors. Virology 1996; 220: 171–176.
67. Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015; 61: 1127–1135.
68. Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 2015; 373: 2608–2617.
69. Jacobson IM, The HCV. Treatment revolution continues: Resistance considerations, pangenotypic efficacy, and advances in challenging populations. Gastroenterol Hepatol (N Y) 2016; 12(10 Suppl 4): 1–11.
70. Patino-Galindo JA, Salvatierra K, Gonzalez-Candelas F, Lopez-Labrador FX. Comprehensive screening for naturally occurring hepatitis C virus resistance to direct-acting antivirals in the NS3, NS5A, and NS5B genes in worldwide isolates of viral genotypes 1 to 6. Antimicrob Agents Chemother 2016; 60: 2402–2416.
71. Bourliere M, Gordon SC, Ramji A, et al. Sofosbuvir/velpatasvir/voxilaprevir for 12 weeks as a salvage regimen in NS5A inhibitor-experienced patients with genotype 1-6 infection: the phase 3 POLARIS-1 study. Hepatology 2016; 64(S1): 102A–103A.
72. Foster GR, Agarwal K, Cramp M, et al. C-ISLE: Grazoprevir/elbasvir plus sofosbuvir in treatment-naive and treatment-experienced HCV GT3 cirrhotic patients treated for 8, 12 or 16 weeks. Hepatology 2016; 64(S1): 39A–40A.
73. Gane E, Lawitz E, Pugatch D, et al. EXPEDITION-4: Efficacy and safety of glecaprevir/pibrentasvir (ABT-493/ABT-530) in patients with renal impairment and chronic hepatitis C virus genotype 1-6 infection. Hepatology 2016; 64 (6-Suppl): 1125A.
74. Poordad F, Gordon S, Asatryan A, et al. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. Hepatology 2017 Jan 27 [Epub ahead of print].
75. Wyles D, Poordad F, Wang S, et al. SURVEYOR-II, part 3: Efficacy and safety of glecaprevir/pibrentasvir (ABT-493/ABT-530) in patients with hepatitis C virus genotype 3 infection with prior treatment experience and/or cirrhosis. Hepatology 2016; 64(S1): 62A–63A.
76. Wyles DL, Wedemeyer H, Reddy KR, et al. Safety and efficacy of the fixed-dose combination regimen of MK-3682/grazoprevir/MK-8408 in cirrhotic or non-cirrhotic patients with chronic HCV GT1 infection who previously failed a direct-acting antiviral regimen (C-SURGE). Hepatology 2016; 64(S1): 101A–102A.
77. Kwo PY. Direct acting antiviral therapy after liver transplantation. Curr Opin Gastroenterol 2016; 32: 152–158.
78. Back DK, Khoo S, Gibbons S, et al. HEP Drug Interactions. Liverpool, UK: Liverpool Drug Interactions Group, University of Liverpool.
79. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Kanwal F, Dulai G. Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: Meta-analysis of clinical studies. Am J Transplant 2005; 5: 2433–2440.
80. Ozkok A, Yildiz A. Hepatitis C virus associated glomerulopathies. World J Gastroenterol 2014; 20: 7544–7554.
81. Hori T, Onishi Y, Kamei H, et al. Fibrosing cholestatic hepatitis C in post-transplant adult recipients of liver transplantation. Ann Gastroenterol 2016; 29: 454–459.
82. Munoz De Bustillo E, Ibarrola C, Colina F, et al. Fibrosing cholestatic hepatitis in hepatitis C virus-infected renal transplant recipients. J Am Soc Nephrol 1998; 9: 1109–1113.
83. Forns X, Charlton M, Denning J, et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology 2015; 61: 1485–1494.
84. Saab S, Jimenez M, Bau S, et al. Treating fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin: A matched analysis. Clin Transplant 2015; 29: 813–819.
85. Issa D, Eghtesad B, Zein NN, et al. Sofosbuvir and simeprevir for the treatment of recurrent hepatitis C with fibrosing cholestatic hepatitis after liver transplantation. Int J Organ Transplant Med 2016; 7: 38–45.
86. Fontana RJ, Brown Jr RS, Moreno-Zamora A, et al. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection. Liver Transpl 2016; 22: 446–458.
87. Coilly A, Fougerou-Leurent C, de Ledinghen V, et al. Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence: The ANRS CUPILT study. J Hepatol 2016; 65: 711–718.
88. Leroy V, Dumortier J, Coilly A, et al. Efficacy of sofosbuvir and daclatasvir in patients with fibrosing cholestatic hepatitis C after liver transplantation. Clin Gastroenterol Hepatol 2015; 13: 1993–2001.e1991-e1992.
89. Manns M, Samuel D, Gane EJ, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: A multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis 2016; 16: 685–697.
90. Reese PP, Abt PL, Blumberg EA, Goldberg DS. Transplanting hepatitis C-positive kidneys. N Engl J Med 2015; 373: 303–305.
91. Durand C, Brown D, Wesson R, et al. EXPANDER-1: Exploring renal transplants using hepatitis-C infected donors for HCV-negative recipients. Am J Transplant 2017;17(Supplement S3). Abstract 2.
92. Goldberg DS, Abt PL, Blumberg EA, et al. Trial of transplantation of HCV-infected kidneys into uninfected recipients. N Engl J Med 2017. [Epub ahead of print].
93. Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): A combination phase 3 study. Lancet 2015; 386: 1537–1545.
94. Pockros PJ, Reddy KR, Mantry PS, et al. Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease. Gastroenterology 2016; 150: 1590–1598.
95. Lo Re 3rd V, Gowda C, Urick PN, et al. Disparities in absolute denial of modern hepatitis C therapy by type of insurance. Clin Gastroenterol Hepatol 2016; 14: 1035–1043.
96. Levitsky J, Verna EC, O'Leary JG, et al. Perioperative ledipasvir-sofosbuvir for HCV in liver-transplant recipients. N Engl J Med 2016; 375: 2106–2108.
97. Cosio FG, Sedmak DD, Henry ML, et al. The high prevalence of severe early posttransplant renal allograft pathology in hepatitis C positive recipients. Transplantation 1996; 62: 1054–1059.
98. Lefaucheur C, Loupy A, Vernerey D, et al. Antibody-mediated vascular rejection of kidney allografts: A population-based study. Lancet 2013; 381: 313–319.